Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19924566 | 1.00 | ITGA4 (0.44) | ITGA4ITGB7ATMMAPTPOLB | |
| SCHEMBL23773085 | 0.86 | AKT1 (0.42) | ITGA4ITGB7ATMMAPTALDH1A1 | |
| SCHEMBL25798251 | 0.85 | ALDH1A1 (0.51) | ITGA4ITGB7ATMMAPTPOLB | |
| SCHEMBL19945772 | 0.83 | MMP8 (0.50) | MAPTPOLBALDH1A1CHRM1 | |
| SCHEMBL19945770 | 0.83 | MMP8 (0.50) | MAPTPOLBALDH1A1CHRM1 | |
| SCHEMBL19945666 | 0.82 | TSHR (0.46) | MAPTALDH1A1CHRM1 | |
| SCHEMBL19945667 | 0.82 | TSHR (0.46) | MAPTALDH1A1CHRM1 | |
| SCHEMBL23000947 | 0.81 | ADAMTS5 (0.50) | MAPTPOLBTDP1ALDH1A1MMP9 | |
| SCHEMBL23000946 | 0.81 | ADAMTS5 (0.50) | MAPTPOLBTDP1ALDH1A1MMP9 | |
| SCHEMBL8724334 | 0.80 | ITGA4 (0.49) | ITGA4ITGB7ATMALDH1A1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111801100-B | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-109641904-B | 7-substituted sulfoxy-purinone compounds for the treatment and prevention of viral infections | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3865482-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| EP-3504210-B1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2021-02-24 | — | — | EP | disclosed |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2020-12-10 | — | — | US | disclosed |
| CN-111801100-A | 7-substituted sulfoxy-purinone compounds and derivatives for the treatment and prevention of liver cancer | 豪夫迈·罗氏有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-20200268762-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER | HOFFMANN-LA ROCHE INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-10752630-B2 | 7-substituted sulfonimidoylpurinone compounds for the treatment of virus infection | HOFMANN LA-ROCHE INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190256515-A1 | NOVEL SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3504210-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2019-07-03 | — | — | EP | disclosed |
| CN-109641904-A | The sulphur imido acyl group purine ketone compound that 7- for treating and preventing virus infection replaces | 豪夫迈·罗氏有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| WO-2018041763-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018041763-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752630-B2 | 7-substituted sulfonimidoylpurinone compounds for the treatment of virus infection | FURIN, UGT1A7, SARS1 | ITGA4 4520/4885ITGB7 2368/4885ATM 4206/4885 |
| US-20190256515-A1 | NOVEL SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, SULT1E1, SULT1A1 | ITGA4 4368/4885ITGB7 4204/4885ATM 4009/4885 |
| US-20200385387-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTION | FURIN, UGT1A7, SARS1 | ITGA4 4520/4885ITGB7 2368/4885ATM 4206/4885 |
| US-20200268762-A1 | 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER CANCER | SULT1E1, SULT1A1, UGT2B7 | ITGA4 4268/4885ITGB7 1815/4885ATM 2511/4885 |
| US-20180072730-A1 | NOVEL 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | TPMT, SULT1E1, UGT1A7 | ITGA4 4246/4885ITGB7 2288/4885ATM 4312/4885 |
| US-10233184-B2 | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | TPMT, UGT1A7, UGT2B7 | ITGA4 4396/4885ITGB7 2060/4885ATM 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.